Related Experiment Video
Updated: Dec 30, 2025
Isolation of Cortical Microglia with Preserved Immunophenotype and Functionality From Murine Neonates
Published on: January 30, 2014
Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson's
Rachel Kelly1, Valerie Joers2, Malú G Tansey2,3
1Pharmacology & Therapeutics, National University of Ireland, H91 W5P7 Galway, Ireland.
Abstract:
Parkinson's disease is a neurodegenerative disorder, the motor symptoms of which are associated classically with Lewy body formation and nigrostriatal degeneration. Neuroinflammation has been implicated in the progression of this disease, by which microglia become chronically activated in response to α-synuclein pathology and dying neurons, thereby acquiring dishomeostatic phenotypes that are cytotoxic and can cause further neuronal death. Microglia have a functional endocannabinoid signaling system, expressing the cannabinoid receptors in addition to being capable of synthesizing and degrading endocannabinoids. Alterations in the cannabinoid system-particularly an upregulation in the immunomodulatory CB2 receptor-have been demonstrated to be related to the microglial activation state and hence the microglial phenotype. This paper will review studies that examine the relationship between the cannabinoid system and microglial activation, and how this association could be manipulated for therapeutic benefit in Parkinson's disease.
Insights
Neuroinflammation in Parkinson's disease involves activated microglia. Targeting the cannabinoid system, especially CB2 receptors, offers potential therapeutic strategies for this neurodegenerative disorder.
Area of Science:
- Neuroscience
- Immunology
- Pharmacology
Background:
- Parkinson's disease (PD) is characterized by motor deficits linked to Lewy bodies and nigrostriatal degeneration.
- Neuroinflammation, driven by chronically activated microglia responding to alpha-synuclein and neuronal death, contributes to PD progression.
- Microglia possess an endocannabinoid system, including cannabinoid receptors and endocannabinoid synthesis/degradation pathways.
Purpose of the Study:
- To review the relationship between the endocannabinoid system and microglial activation in Parkinson's disease.
- To explore the therapeutic potential of manipulating the cannabinoid system for PD treatment.
Main Methods:
- Literature review of studies investigating the endocannabinoid system in microglia within the context of Parkinson's disease.
- Analysis of research on cannabinoid receptor (CB2) upregulation and its correlation with microglial activation states.
Main Results:
- The endocannabinoid system, particularly the CB2 receptor, is altered in activated microglia in PD.
- CB2 receptor modulation is linked to microglial phenotypes and inflammatory responses relevant to PD pathogenesis.
Conclusions:
- The endocannabinoid system, especially CB2 receptors on microglia, represents a promising therapeutic target for Parkinson's disease.
- Modulating microglial activation via the cannabinoid system could offer neuroprotective benefits in PD.
More Related Videos
Related Concept Videos
01:15Parkinson's Disease: Overview
01:24Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
01:37Neural Regulation